Our News on Newswise

Tip Sheet: How to diversify vaccine clinical trials, 30 years of science education, Trevor Noah talks to Hutch scientists — and more

SEATTLE — Nov. 2, 2021 — Below are summaries of recent Fred Hutch research findings and other news.
2-Nov-2021 5:15 PM EDT Add to Favorites

Monoclonal antibody treatment highly effective at reducing COVID-19 hospitalizations

Researchers published interim results in The New England Journal of Medicine from a Phase 3 study of the COVID-19 monoclonal antibody treatment sotrovimab, sponsored by Vir Biotechnology and GlaxoSmithKline. The study found that compared to the...
28-Oct-2021 2:05 PM EDT Add to Favorites

Tip Sheet: New MacArthur ‘genius,’ returning to school during COVID-19 and the science of race and racism

SEATTLE — Oct. 5, 2021 — Below are summaries of recent Fred Hutch research findings and other news.
5-Oct-2021 4:50 PM EDT Add to Favorites

Tip Sheet: Making clinical trials more inclusive, measuring COVID vaccine protection and new HIV vaccine results

SEATTLE — September 1, 2021 — Below are summaries of recent Fred Hutch research findings and other news.
1-Sep-2021 4:05 PM EDT Add to Favorites

Experimental Phase 2b HIV Vaccine Regimen Provides Insufficient Protection in Preventing HIV

A primary analysis of an experimental HIV vaccine regimen being studied in a high-incidence population of young women in sub-Saharan Africa found the experimental vaccine did not provide sufficient protection against HIV infection.
31-Aug-2021 8:20 AM EDT Add to Favorites

Persistent COVID-19 Infections in Immunocompromised People May Give Rise to Variants of Concern

In an article in the New England Journal of Medicine, scientists from Fred Hutchinson Cancer Research Center, Johns Hopkins Bloomberg School of Medicine, the U.S. Military HIV Research Program and the Institute for Global Health and Infectious...
5-Aug-2021 8:45 AM EDT Add to Favorites

One in Four Cancer Patients Lack Sufficient Immunity Against Measles and Mumps, Study Finds

One in four cancer patients lack sufficient immunity against measles and mumps, study finds
28-Jul-2021 12:15 PM EDT Add to Favorites

Fred Hutchinson Cancer Research Center, Seattle Children's and UW Medicine Lay Groundwork for Historic Cancer Partnership

SEATTLE — July 13, 2021 — Fred Hutchinson Cancer Research Center, UW Medicine, Seattle Cancer Care Alliance and Seattle Children’s today announced plans to explore restructuring their longtime relationship to accelerate a d mission of...
13-Jul-2021 12:55 PM EDT Add to Favorites


See All News

Our Experts on Newswise

Newswise: David_Maloney_2017-Robert_Hood_FHNS.jpg

NEJM to Pub 2 CAR T-Cell Therapy Studies. David Maloney, Head of Fred Hutch Clinical Immunotherapy Research, Can Discuss

8-Dec-2017 2:05 PM EST

Newswise: David_Maloney_FDA_Statement.jpg

Fred Hutch statement on FDA’s CAR T-cell decision

18-Oct-2017 6:05 PM EDT

Newswise: David_Maloney_2017 -(Robert_Hood_FHNS).jpg

FDA's CTL019 Ruling Validates Importance of Similar Lifesaving Cellular Immunotherapies Currently Being Developed and Tested by Fred Hutch and Other NCI-Designated Cancer Centers

30-Aug-2017 12:05 PM EDT

Newswise: Eric_Holland.jpg

Fred Hutch Glioblastoma Experts Available to Discuss Diagnosis, Treatment Options and the Latest Research

20-Jul-2017 5:05 PM EDT

Newswise: Duggan_Catherine.jpg

Embargoed Research: In Fred Hutch Study, Obese Women Who Lost Weight Significantly Lowered Levels of Proteins in the Blood That Help Certain Tumors Grow

12-Jul-2016 12:05 AM EDT

Newswise: RuthEtzioni.jpg

Fred Hutch Expert Available to Discuss New Recommendations for Colorectal Cancer Screening

15-Jun-2016 6:05 PM EDT

Newswise: GaryLyman.jpg

Fred Hutch Expert Available to Discuss NEJM Article on Biomarker Tests for Molecularly Targeted Therapies

Gary H. Lyman, MD, MPH, an internationally recognized oncologist and health economist at Fred Hutchinson Cancer Research Center and a member of a committee of the National Academies of Sciences, Engineering, and Medicine (NASEM), is available to...
14-Jun-2016 1:05 AM EDT

Newswise: AmandaPaulovich_229451.jpg

Expert Available to Discuss New Study About the Future of Personalized Breast Cancer Treatment

If you’re seeking an expert to discuss a new study (in Nature) about the future of personalized breast cancer treatment, Dr. Amanda (Mandy) Paulovich, Oncologist and Geneticist at Fred Hutchinson Cancer Research Center and one of the study’s...
25-May-2016 1:05 PM EDT

See All Experts

Our YouTube Videos

About

At Fred Hutchinson Cancer Research Center, home to three Nobel laureates, interdisciplinary teams of world-renowned scientists seek new and innovative ways to prevent, diagnose and treat cancer, HIV/AIDS and other life-threatening diseases. Fred Hutch’s pioneering work in bone marrow transplantation led to the development of immunotherapy, which harnesses the power of the immune system to treat cancer with minimal side effects. An independent, nonprofit research institute based in Seattle, Fred Hutch houses the nation’s first and largest cancer prevention research program, as well as the clinical coordinating center of the Women’s Health Initiative and the international headquarters of the HIV Vaccine Trials Network. Private contributions are essential for enabling Fred Hutch scientists to explore novel research opportunities that lead to important medical breakthroughs. For more information visit www.fredhutch.org or follow Fred Hutch on Facebook, Twitter or YouTube.

Experts

Contacts

Anna Altavas
Communications Manager, HIV Vaccine Trials Network & COVID-19 Prevention Network

aaltavas@fredhutch.org

Shelby Barnes
Sr Director Communications

mrbarnes@fredhutch.org

206-667-1455

Claire Hudson
Communications Manager

crhudson@fredhutch.org

206-667-7365

Molly McElroy
Communications Manager
science

mwmcelro@fredhutch.org

206-667-6651

David Patton
Senior Director Content Strategy

dpatton@fredhutch.org

206-667-3503

Sandy Van
Public Relations Consultant

sandy@prpacific.com

808-526-1708

Kat Wynn
Communications Specialist
General

kwynn@fredhutch.org

360-675-2758

Twitter

close
0.44508